menu search

Aerami therapeutics announces presentation of phase 1 clinical trial data for lead program aer-901 at the 2023 european respiratory society (ers) international congress

DURHAM, N.C., Sept. 12, 2023 (GLOBE NEWSWIRE) — Aerami Therapeutics (“Aerami”), a clinical stage biopharmaceutical company dedicated to breathin...

September 12, 2023, 1:48 pm

Alnylam's (alny) zilebesiran meets goals in mid-stage study

Alnylam's (ALNY) mid-stage study of zilebesiran in the treatment of hypertension in patients at high cardio...

September 8, 2023, 8:17 am

Global angiography catheters market sees bright prospects, targeting us$ 2.7 billion by 2033 | persistence market research

Growing Prevalence of cardiovascular Diseases and Increasing Rate of Surgical Admissions are Factors Pr...

September 6, 2023, 10:38 am

Biocardia announces interim efficacy results in phase iii pivotal cardiamp cell therapy heart failure trial

SUNNYVALE, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the...

September 5, 2023, 11:15 am

Ischemia reperfusion injury therapeutics market revenue to cross usd 3.2 billion by 2031 at a cagr of 3.5%: transparency market research inc.

Increasing prevalence of cardiovascular diseases, increase in geriatric population and surge in awarene...

September 4, 2023, 10:10 am

Fitness equipment home & gym training market worth usd 157.6261 billion by 2030 globally, at a cagr of 5.86%, says market research future

Fitness Equipment Home & Gym Training Market Research Report: Information By Application (Residential and Commercial), Product Type (...

August 29, 2023, 5:00 am

Bridgebio presents detailed positive results from phase 3 attribute-cm study of acoramidis for patients with transthyretin amyloid cardiomyopathy (attr-cm) at european society of cardiology congress 2

– The primary endpoint was met (Win Ratio of 1.8) with a highly statistically significant p-value (p<0.0001); this primary endpoint result consisten...

August 27, 2023, 10:15 am

Bridgebio presents detailed positive results from phase 3 attribute-cm study of acoramidis for patients with transthyretin amyloid cardiomyopathy (attr-cm) at european society of cardiology congress 2

– The primary endpoint was met (Win Ratio of 1.8) with a highly statistically significant p-value (p<0.0001); this primary endpoint result consisten...

August 27, 2023, 10:15 am

Bridgebio presents detailed positive results from phase 3 attribute-cm study of acoramidis for patients with transthyretin amyloid cardiomyopathy (attr-cm) at european society of cardiology congress 2

– The primary endpoint was met (Win Ratio of 1.8) with a highly statistically significant p-value (p<0.0001); this primary endpoint result consisten...

August 27, 2023, 10:15 am

Bridgebio presents detailed positive results from phase 3 attribute-cm study of acoramidis for patients with transthyretin amyloid cardiomyopathy (attr-cm) at european society of cardiology congress 2

– The primary endpoint was met (Win Ratio of 1.8) with a highly statistically significant p-value (p<0.0001); this primary endpoint result consisten...

August 27, 2023, 10:15 am

Bridgebio presents detailed positive results from phase 3 attribute-cm study of acoramidis for patients with transthyretin amyloid cardiomyopathy (attr-cm) at european society of cardiology congress 2

– The primary endpoint was met (Win Ratio of 1.8) with a highly statistically significant p-value (p<0.0001); this primary endpoint result consisten...

August 27, 2023, 10:15 am

Esperion presents two clear outcomes study late-breakers at european society of cardiology congress 2023

– In total cardiovascular event analysis, bempedoic acid shows 20% risk reduction in MACE-4 and 17% r...

August 26, 2023, 3:00 pm

Biosig (bsgm) grows in arrhythmia care with subscription model

BioSig's (BSGM) subscription model for PURE EP provides electrophysiologists and cardiology departments...

August 25, 2023, 11:17 am

Bridgebio pharma to present detailed results from the phase 3 attribute study in patients with transthyretin amyloidosis cardiomyopathy (attr-cm) at european society of cardiology (esc) congress 2023

PALO ALTO, Calif., Aug. 24, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage...

August 24, 2023, 4:01 pm

3 massive new markets could await ozempic, and they might make novo nordisk investors richer

The active ingredient in Ozempic could be useful for quite a few conditions. cardiovascular disease, ce...

August 24, 2023, 5:40 am

Masimo's (masi) pvi favored by study for gdft in elderly patients

Masimo's (MASI) non-invasive, continuous PVi is expected to reduce cardiopulmonary complications and fl...

August 22, 2023, 2:17 pm

Newamsterdam pharma: best cardiovascular biotech in 2023

NewAmsterdam Pharma showcased positive trajectory in Q2 2023 financial report, with over-enrollment in obicetrapib's Ph.3 BROADWAY trial indicating ro...

August 19, 2023, 1:10 pm

Applied therapeutics: buy for upcoming pre-nda meeting (i expect a positive outcome)

Applied Therapeutics is a micro-cap with low cash balance, but has major upcoming catalysts (pre-NDA meeting for galactosemia and phase 3 results in d...

August 17, 2023, 4:28 am

Intracardiac echocardiography market to surpass usd 979.5 million by 2031, expanding at a cagr of 5.3%: tmr report

Increase in prevalence of cardiac diseases and the rise in the geriatric population are projected to fuel the global intracardiac echo...

August 16, 2023, 3:16 pm

cardiol therapeutics inc. (crdl) upgraded to buy: here's what you should know

cardiol Therapeutics Inc. (CRDL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimis...

August 16, 2023, 1:14 pm


Search within

Pages Search Results: